21. Yang JC, Wu YL, Schuler M, et al. Afatinib vs. cisplatin- based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): ...
確定! 回上一頁